DESIGN AND SYNTHESIS OF NEW MOLECULES BASED ON THIOLACTOMYCIN AS POTENTIAL ANTITUBERCULAR, ANTIMALARIAL AGENTS AND ENANTIOSELECTIVE SYNTHESIS OF (3R,4R), (3S,4S)- DIHYDROXYPYRROLIDINES by SHAIK, AZEEZA
SHAIK THESIS 
 11 
 
 
 
 
 
 
 
 
SYNOPSIS 
 
 
 
 
 
 
 
 
 
 
SHAIK THESIS 
 12 
The work in this thesis entitled “Design and synthesis of new molecules 
based on thiolactomycin as potential antitubercular, antimalarial agents and 
enantioselective synthesis of (3R,4R), (3S,4S)-dihydroxypyrrolidines” has 
been undertaken with aim to develop new antitubercular as well as 
antimalarial agents, eventually leading to new drugs for the effective treatment 
of tuberculosis and malaria. Further, the other objective is to develop new 
enantioselective approaches for the synthesis of bio-active compounds and 
intermediates. The research work carried out has been described in five 
chapters. 
Chapter-1: Introduction– Tuberculosis, Malaria and Enantioselective 
synthesis 
This chapter provides an overview on tuberculosis and its related aspects like 
current chemotherapeutics, causes for resistance, desirable features for new 
drugs and the targets for intervention of new drugs. In addition to this, it 
provides an account on malaria and the development of new drugs for its 
treatment. Further, it also provides a concise account on the enantioselective 
routes for the synthesis of biologically important compounds and 
intermediates.  
Chapter-2: Design and Synthesis of Conformationally Flexible 
Thiomorpholino, Piperidino Conjugates of Thiolactone and Related Dimers 
Active against M. tuberculosis and P. falciparum 
In the drug discovery, one approach is to trace back antibiotic natural products 
to “lead structures” and improve their activity by variation of the substituents. 
In this perspective, the naturally occurring (5R)-thiolactomycin (TLM, 1) 
produced by the actinomycetes Nocardia species is active against number of 
pathogens including Mycobacterium tuberculosis and Plasmodium falciparum. The 
interest in TLM is stimulated by its rapid absorption in tissues, its effectiveness 
in mouse infection models, and its low toxicity in animals. On a molecular 
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level, 1 is an inhibitor of the bacterial but not human enzymes that convert 
malonyl acyl carrier protein (malonyl-ACP) and the acyl-ACP intermediates of 
growing chain lengths through β-ketoacyl-ACPs (KasA, KasB and FABH) into 
lipids. Although the pharmaco profile of TLM is interesting, it is still 
insufficient to warrant further progression of thiolactomycin itself either as an 
antitubercular or antimalarial agent. Therefore, new molecules by structural 
modification on thiolactomycin backbone need to be designed with improved 
activities. 
This chapter describes the design of conformationally flexible thiomorpholino, 
piperidino conjugates of thiolactone and related dimers based on the fitness 
and interactions with Mycobacterium β-ketoacyl-acyl carrier protein (FABH). 
The designed conjugates have been synthesized and biologically evaluated 
against M. tuberculosis H37Rv, and P. falciparum D10 strains.  
SO
OH
(5R)-Thiolactomycin  1  
Figure 1 
The key intermediate of thiolactomycin, 4-hydroxy thiolactone ring 6 has been 
synthesized starting from methylpropionyl acetate (2) as depicted in Scheme 1. The 
methylation of 2 in THF with methyl iodide provides methylated β-ketoester 3, 
which on bromination with bromine provides γ-bromo-β-ketoester (4). The 
thioacetylation of 4 is carried out by thioacetic acid to give γ-thioacetylated β-
ketoester (5), which on cyclization on treatment with alcoholic KOH affords the 
required precursor 4-hydroxy thiolactone ring 6 in good yield. 
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Reagents and conditions: i) anhydrous K2CO3, CH3I, dry THF; ii) Br2, CHCl3; iii) AcSH, 
Et3N, CH2Cl2; iv) KOH, H2O-EtOH. 
The bromoalkyl derivatives of thiolactone (7a-i) has been synthesized by the 
base catalyzed condensation of 4-hydroxythiolactone 6 with excess amount of 
dibromoalkanes of varying alkyl chain lengths (1,2-dibromoethane, 1,3-
dibromopropane, 1,4-dibromobutane, 1,5-dibromopentane, 1,6-
dibromohexane, 1,8-dibromooctane, 1,9-dibromononane, 1,10-dibromodecane 
and 1,12dibromododecane) under reflux conditions. Further, these 
bromoderivatives of thiolactone 7a-i have been condensed with 
thiomorpholine and piperdine employing anhydrous potassium carbonate as 
base under reflux conditions to provide 8a-i, 9a-i in good yields (Scheme 2). In 
addition, conformationally flexible dimers of thiolactone 10d-i has been 
synthesized by treating with dibromoalkanes having different methylene 
spacers (n = 5, 6, 8, 9, 10, 12) in good yields. Similarly, the piperazine and 
homopiperazine linked thiolactone dimers with different methylene spacers 
(11d-i, 12d-i) are also synthesized employing anhydrous potassium carbonate 
in good yields.  
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Scheme 2 
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Reagents and conditions: i) Br-(CH2)n-Br (4equiv), K2CO3, dry acetone, reflux, 48h; ii) 
thiomorpholine; iii) piperidine; iv) ) Br-(CH2)n-Br (0.5 equiv); v) piperazine (0.5 equiv); 
vi) homopiperazine (0.5 equiv). 
The synthesized novel thiolactomycin based analogues has been evaluated for 
the ability to inhibit the growth of M. tuberculosis H37Rv and Plasmodium 
falciparum D10 strains. All these compounds have shown moderate to good 
activity.  The thiolactone dimer conjugated with homopiperazine with 10-
carbon methylene spacer 12h has shown good antimycobacterial activity 
having MIC value of 4 µg/mL. The analogue 7b, with a 3-carbon methylene 
spacer, exhibited the promising antiplasmodial activity with an IC50 value of 
0.2 µM. These investigations suggest that modification at C-4 of thiolactomycin 
is preferable for the development of new antitubercular and antimalarial agents 
with improved activity. 
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Chapter–3: Design, Synthesis and Biological Evaluation of Arylsulfonamido 
Conjugates of Thiolactone against M. tuberculosis and P. falciparum 
This chapter describes the design and synthesis of novel libraries of 
thiolactomycin conjugates based on bioinformatics studies with FABH protein. 
Further, these molecules have been biologically evaluated against M. 
tuberculosis and P. falciparum strains. 
The key intermediate 6 required for the synthesis of arylsulfonamido 
conjugates of thiolactone have been synthesized according to the route 
described in earlier chapter. Further, the bromoderivatives of thiolactone 
having different methylene spacers 7a-i (n=2, 3, 4, 5, 6, 8, 9, 10, 12) on 
condensation reaction with different N-substituted arylsulfonylpiperazines 
25a-h, 4-(phenylsulfonyl)azetidin-2-one and saccharin provides the 
corresponding arylsulfonamido conjugates of thiolactone 13a-i, 14a-i, 15d-i, 
16f-i, 17f-i, 18a-i, 19c-i, 20f-i, 21f-i and 22a-i in good yields (Scheme 3).  
Scheme 3 
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Reagents and conditions: i) Br-(CH2)n-Br (4equiv), K2CO3, dry acetone, reflux, 48h; ii) N-
(phenylsulfonyl)piperazine; iii) N-tosylpiperazine; iv) N-(4-
acetamidophenylsulfonyl)piperazine; v) N-(4-fluorophenylsulfonyl)piperazine; vi) N-
(2,4-difluorophenylsulfonyl)piperazine; vii) 4-(phenylsulfonyl)azetidin-2-one; viii) N-
(8-quinolylsulfonyl)piperazine; ix) N-(1-naphthylsulfonyl)piperazine; x) N-(2-
naphthylsulfonyl)piperazine; xi) saccharin. 
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The arylsulfonylpiperazine intermediates (25a-h) has been synthesized by the 
treatment of different arylsulfonyl chlorides with excess of piperazine as 
shown in scheme 4. 
Scheme 4 
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23h;  R = 2-naphthyl  
Reagents and conditions: i) MeOH, 2-3h. 
The synthesized library of these new arylsulfonamido conjugates of thiolactone 
have been evaluated against M. tuberculosis H37Rv and CQ-sensitive strains of 
P. falciparum. Amongst them, the phenylsulfonamido conjugates of thiolactone 
with twelve and ten spacers have been found to be most active against 
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tuberculosis with a MIC value of 5 µg/mL. Further, most of these conjugates 
have exhibited moderate to good antimalarial activity. 
Chapter-4: Design, and Synthesis of Novel Quinolylpiperazino Conjugates 
of Thiolactone as Potential Antitubercular and Antimalarial Agents  
This chapter deals with the design of a library of 
quinolylpiperazino/hompiperazino conjugates of thiolactone, based on the 
bioinformatic data obtained by the fitness interactions of these conjugates with 
FABH protein. The designed conjugates (26-29a-f) have been synthesized by 
the condensation of bromoalkyl derivatives of thiolactone 7a-f having different 
carbon-methylene spacers (n = 5, 6, 8, 9, 10, 12) with 
quinolylpiperazine/quinolylhomopiperazines (31a-b, 32a-b) in the presence of 
anhydrous potassium carbonate under reflux conditions in good yields as 
shown in Scheme 5. 
The precursors quinolylpiperazines/homopiperazines (31a-b, 32a-b) required 
for the synthesis of target compounds have been obtained by the condensation 
of 7-trifluoromethyl-4-chloroquinoline/4,7-dichloroquinoline with piperazine 
and homopiperazine in dry acetone under basic reflux conditions (Scheme 6). 
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Reagents and conditions: i) Br-(CH2)n-Br (4equiv), K2CO3, dry acetone, reflux, 48h; ii) N-
(7-chloro-4-quinolyl)piperazine/N-(7-trifluoromethyl-4-quinolyl)piperazine; iii) N-(7-
chloro-4-quinolyl)homopiperazine/N-(7-trifluoromethyl-4-quinolyl)homopiperazine. 
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Scheme 6 
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Reagents and conditions: i) piperazine, K2CO3, dry acetone, reflux, 48h; ii) 
homopiperazine. 
The designed and synthesized quinolylpiperazino/homopiperazino conjugates 
of thiolactone have been evaluated against the strains of Mycobacterium 
tuberculosis and Plasmodium falciparum. Some of the molecules have shown 
excellent inhibitory activities against tuberculosis and malaria. Of them, the 7-
trifluoromethylquinolylpiperazino conjugate 26f has shown remarkable 
antimycobacterial activity equal to that of isoniazid having MIC value of 0.5 
µg/mL. Interestingly, this new thiolactomycin based compound 26f have also 
displayed 128 folds more potent activity than rifampicin against rifampicin 
resistant strains and 256 folds more potent activity than isoniazid against 
MDR-strains, which lead to filing of a patent. Further, compound 26f is non-
toxic and exhibited good in vivo activity in mouse models. The detailed 
mechanistic and preclinical safety studies are under progress to explore its 
clinical potential.  
Chapter-5: Enantioselective Synthesis of (3R,4R)- and (3S,4S)-
Dihydroxypyrrolidines by an Efficient Lipase Mediated Resolution Protocol 
This chapter describes the enantioselective synthesis of (3R,4R)- and (3S,4S)-
dihydroxypyrrolidines in high enantiopurity by employing an efficient lipase 
mediated resolution protocol. The enantiomerically pure trans 3,4-
dihydroxypyrrolidines 33, are useful intermediates for the synthesis of 
biologically active Sialyl Lewis X-mimetics 34 (potential anti-inflammatory 
agents), new carbapenems 35 (β-lactam antibiotics with broad spectrum of 
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antibacterial activity) cephalosporin antibiotics (36, 37), etc. The reported 
approaches either provide only a single isomeric form of these important 
intermediates or proceeds with poor yields. Since the biological effects of these 
trans 3,4-dihydroxypyrrolidines varies considerably with stereochemistry, this 
underlines the need of methods which provide access to both enantiomers.  
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Figure 2 
The racemic 1-Cbz-trans-3-acetyloxy-4-hydroxypyrrolidine 41 required for the 
resolution process is prepared via convenient route in quantitative yields. The 
synthetic strategy starts with protection of secondary amine on commercially 
available and inexpensive diallylamine 38 to provide Cbz-protected 
diallylamine, which on ring-closing metathesis (RCM) by employing Grubbs’ 
catalyst (Ist generation) affords N-Cbz-3-pyrroline 39. The formation of 
pyrrolidine epoxide 40 has been achieved in two steps via trans-bromohydrin 
with N-bromosuccinimide followed by basification of it with 1N sodium 
hydroxide. Finally, the epoxide 40 has been refluxed with potassium acetate in 
acetic acid for overnight to provide the required precursor 3-acetyloxy-4-
hydroxypyrrolidine 41 for the lipase-mediate kinetic resolution (Scheme 7). 
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Scheme 7  
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Reagents and conditions: i) CbzCl, Et3N, CH2Cl2, rt; ii) Grubbs 1st generation, CH2Cl2, rt; 
iii) NBS, DMSO-H2O, rt; iv) 1N NaOH, rt; v) AcOK/AcOH, reflux. 
An extensive investigation has been undertaken to develop an efficient 
resolution protocol by screening different commercially available lipases. In 
addition, the effects of solvents, acyl donors and different resolution processes 
have been studied. Based on these investigations, the lipase-catalyzed 
alcoholysis of 3-acetyloxy-4-hydroxypyrrolidine (±)-41 has been selected and 
carried out by employing papain (2 equivalents w/w) and n-butanol in 
diisopropyl ether (Scheme 8). This reaction process is monitored on chiral 
HPLC employing Chiralcel AD-H column to provide acetate (3S,4S)-41 in 98% 
ee and the corresponding alcohol (3R,4R)-33 in 90% ee. Finally the monoacetate 
(3R,4R)-41, is subjected to deacetylation under mild conditions using 
anhydrous potassium carbonate in methanol to afford (3R,4R)-33 with 
retention of configuration and enantiopurity. 
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Reagents and conditions: i) papain, n-BuOH, DIPE; (ii) K2CO3, MeOH. 
 
